Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

Prostate cancers display a variable range of clinical behaviors, from slow-growing tumors of little clinical significance to aggressively metastatic andlethal diseases. Current biochemical prognostic tools, such as pre-operative prostate specific antigen (PSA) levels, are used to place men in low-, intermediate-, and high-risk prostate cancer risk groupings. However, these prognostic tools often fail to accurately stratify individual patients at early stages of the disease. The predictive power of previously identified cytogenetic profiles help choosing the proper diagnosis, and are critical to characterize each patient and influence post-operative treatment strategies decision and provide a more specific follow.

8q24, cMYC 8p22, LPL 10q23, PTEN Xq12, SMAX1